[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
August 13, 1982

Antiandrogen effects of ulcer drug averted with experimental agent

JAMA. 1982;248(6):621-622. doi:10.1001/jama.1982.03330060003001

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


Impotence has been reported to occur in a few men taking cimetidine for duodenal or gastric ulcers. In fact, in a study reported at the recent Digestive Disease Week meetings in Chicago, impotence, breast tenderness, and gynecomastia occurred in almost half of a small group of men taking high doses of cimetidine.

These adverse effects disappeared, however, in those of the men who were switched to the investigational agent ranitidine, also an H2-receptor antagonist which has been used for some years in Europe.

The study, described by gastroenterologist Robert T. Jensen, MD, senior investigator at the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases, Bethesda, Md, was carried out by Jensen and colleagues at that institute and elsewhere at the National Institutes of Health (NIH). The 19 patients in the study had either Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Doses of cimetidine used to control